Literature DB >> 25428649

An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Stephanie Albin1, Charlotte Cunningham-Rundles.   

Abstract

For patients with significant antibody deficiencies, immunoglobulin therapy is the mainstay of treatment as it significantly reduces both the frequency and severity of infections. The formulations and delivery methods of immunoglobulin have evolved over time, and continued improvements have allowed for increased access to this effective medication. This review is an update on the current status of immunoglobulin therapy in immunodeficiency disorders, and discusses the mechanisms, forms and dosing, and indications for immunoglobulin replacement.

Entities:  

Keywords:  antibody deficiency; immunoglobulin replacement; intravenous immunoglobulin; mechanisms of immunoglobulin; primary immunodeficiency; subcutaneous immunoglobulin

Mesh：

Substances：

Year:  2014        PMID： 25428649      PMCID： PMC4324501          DOI： 10.2217/imt.14.67

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  89 in total

1.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011).

Authors:  James W Verbsky; Mei W Baker; William J Grossman; Mary Hintermeyer; Trivikram Dasu; Benedetta Bonacci; Sreelatha Reddy; David Margolis; James Casper; Miranda Gries; Ken Desantes; Gary L Hoffman; Charles D Brokopp; Christine M Seroogy; John M Routes
Journal:  J Clin Immunol       Date:  2011-11-10       Impact factor: 8.317

3.  The health status and quality of life of adults with X-linked agammaglobulinemia.

Authors:  Vanessa Howard; Jeffrey M Greene; Savita Pahwa; Jerry A Winkelstein; John M Boyle; Mehmet Kocak; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2005-12-22       Impact factor: 3.969

Review 4.  Overview of routes of IgG administration.

Authors:  Troy R Torgerson
Journal:  J Clin Immunol       Date:  2012-12-11       Impact factor: 8.317

Review 5.  Why I use subcutaneous immunoglobulin (SCIG).

Authors:  Ralph S Shapiro
Journal:  J Clin Immunol       Date:  2012-12-21       Impact factor: 8.317

Review 6.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

7.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

Review 8.  Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics.

Authors:  Craig Giragossian; Tracey Clark; Nicole Piché-Nicholas; Christopher J Bowman
Journal:  Curr Drug Metab       Date:  2013-09       Impact factor: 3.731

9.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

Review 10.  Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections.

Authors:  Ari J Fried; Francisco A Bonilla
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132
View more
  18 in total

Review 1.  Common Variable Immunodeficiency and Liver Involvement.

Authors:  Junmin Song; Ana Lleo; Guo Xiang Yang; Weici Zhang; Christopher L Bowlus; M Eric Gershwin; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

2.  Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID).

Authors:  Ali Zarezadeh Mehrabadi; Nazanin Aghamohamadi; Hassan Abolhassani; Asghar Aghamohammadi; Nima Rezaei; Reza Yazdani
Journal:  J Clin Immunol       Date:  2022-01-27       Impact factor: 8.317

Review 3.  Primary Immunodeficiencies: Diseases of Children and Adults - A Review.

Authors:  Aleksandra Lewandowicz-Uszyńska; Gerard Pasternak; Jerzy Świerkot; Katarzyna Bogunia-Kubik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  PROTECTIVE LEVELS OF VARICELLA-ZOSTER ANTIBODY DID NOT EFFECTIVELY PREVENT CHICKENPOX IN AN X-LINKED AGAMMAGLOBULINEMIA PATIENT.

Authors:  Fernanda Aimée Nobre; Isabela Garrido da Silva Gonzalez; Maria Isabel de Moraes-Pinto; Beatriz Tavares Costa-Carvalho
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Sep-Oct       Impact factor: 1.846

5.  Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.

Authors:  Richard L Wasserman; William Lumry; James Harris; Robyn Levy; Mark Stein; Lisa Forbes; Charlotte Cunningham-Rundles; Isaac Melamed; Ai Lan Kobayashi; Wei Du; Roger Kobayashi
Journal:  J Clin Immunol       Date:  2016-06-20       Impact factor: 8.317

6.  Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.

Authors:  Soyoung Lee; Han Wool Kim; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

7.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

8.  Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).

Authors:  Alessandra Vultaggio; Chiara Azzari; Silvia Ricci; Baldassarre Martire; Valentina Palladino; Vera Gallo; Antonio Pecoraro; Claudio Pignata; Giuseppe Spadaro; Simona Graziani; Viviana Moschese; Antonino Trizzino; Giorgio Maria Boggia; Andrea Matucci
Journal:  J Clin Immunol       Date:  2018-06-28       Impact factor: 8.317

9.  X-linked agammaglobulinemia (XLA):Phenotype, diagnosis, and therapeutic challenges around the world.

Authors:  Zeinab A El-Sayed; Irina Abramova; Juan Carlos Aldave; Waleed Al-Herz; Liliana Bezrodnik; Rachida Boukari; Ahmed Aziz Bousfiha; Caterina Cancrini; Antonio Condino-Neto; Ghassan Dbaibo; Beata Derfalvi; Figen Dogu; J David M Edgar; Brian Eley; Rasha Hasan El-Owaidy; Sara Elva Espinosa-Padilla; Nermeen Galal; Filomeen Haerynck; Rima Hanna-Wakim; Elham Hossny; Aydan Ikinciogullari; Ebtihal Kamal; Hirokazu Kanegane; Nadia Kechout; Yu Lung Lau; Tomohiro Morio; Viviana Moschese; Joao Farela Neves; Monia Ouederni; Roberto Paganelli; Kenneth Paris; Claudio Pignata; Alessandro Plebani; Farah Naz Qamar; Sonia Qureshi; Nita Radhakrishnan; Nima Rezaei; Nelson Rosario; John Routes; Berta Sanchez; Anna Sediva; Mikko Rj Seppanen; Edith Gonzalez Serrano; Anna Shcherbina; Surjit Singh; Sangeetha Siniah; Guiseppe Spadaro; Mimi Tang; Ana Maria Vinet; Alla Volokha; Kathleen E Sullivan
Journal:  World Allergy Organ J       Date:  2019-03-22       Impact factor: 4.084

10.  Duration of frequent or severe respiratory tract infection in adults before diagnosis of IgG subclass deficiency.

Authors:  James Barton; Clayborn Barton; Luigi Bertoli
Journal:  PLoS One       Date:  2019-05-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.